Please use this identifier to cite or link to this item:
Title: Darbepoetin Alfa effectively treats Anemia in patients with chronic kidney disease with De Novo Every-Other-Week administration
Authors: Toto, Robert ;Pichette, Vincent ;Navarro, Jesus ;Brenner, Robert ;Carroll, Wendi ;Liu, Wei ;Roger, Simon D 
Issue Date: Aug-2004
Source: Volume 24, Issue 4, pp. 453-460
Journal title: American Journal of Nephrology
Abstract: AIM: This multicenter, open-label study determined safety and efficacy of once-every-other-week administration of darbepoetin alfa for anemia of chronic kidney disease in erythropoietin-naive patients not on dialysis. METHODS: Participants with hemoglobin levels <11.0 g/dl at baseline were administered darbepoetin alfa at an initial dosage of 0.75 microg/kg once every other week. The dose was titrated to achieve and maintain a hemoglobin response, defined as a hemoglobin range of between 11.0 and 13.0 g/dl for up to 24 weeks. The primary end point was the dose of darbepoetin alfa at initial hemoglobin response. RESULTS: Six hundred and eight patients were enrolled, and 463 completed the study; 95% (95% confidence interval: 0.93, 0.97) of the patients who completed treatment achieved a hemoglobin response. The mean darbepoetin alfa dose at the time of response was 63.5 +/- (SD) 16.9 microg, and the mean time to hemoglobin response was 5.7 +/- (SD) 4.5 weeks. Oral iron therapy was administered to 60% and intravenous iron to 16% of the participants. Darbepoetin alfa was well tolerated, and adverse events were consistent with those expected in patients with chronic kidney disease. CONCLUSION: Darbepoetin alfa administered once every other week is effective and safe for achieving and maintaining target hemoglobin levels in anemic patients with chronic kidney disease.
DOI: 10.1159/000080452
ISSN: 0250-8095
Publicaton type: Journal Article
Keywords: Kidney Disease
Study or Trial: Multicentre Studies
Appears in Collections:Renal Medicine

Show full item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.